<DOC>
	<DOCNO>NCT00493129</DOCNO>
	<brief_summary>Primary Objective : 1 . To assess response rate ONTAK Systemic Mastocytosis ( SM ) patient . Secondary Objectives : 1 . To assess safety ONTAK SM patient . 2 . To evaluate time progression duration response follow treatment ONTAK .</brief_summary>
	<brief_title>Ontak ( Denileukin Diftitox ) Patients With Systemic Mastocytosis ( SM )</brief_title>
	<detailed_description>Denileukin diftitox use treatment variety disorder , particular , malignant lymphoma , another blood-related disease . Denileukin diftitox believe able specifically attach kill malignant mast cell . Before start treatment study , call `` screening test '' . These test help doctor decide eligible take part study . You blood ( around 2 teaspoon ) bone marrow sample collect . To collect bone marrow sample , area hip bone numb anesthetic small amount bone marrow withdrawn large needle . These sample use test confirm diagnosis disease . Women able child must negative blood pregnancy test . If find eligible , receive denileukin diftitox injection vein day 5 day row . This repeat every 3 week ( 1 cycle ) . You receive treatment outpatient basis . Treatment continue long evidence therapy affect disease beneficial . If disease get bad experience intolerable side effect , take study doctor discus treatment option . During treatment blood ( around 1 teaspoon ) collect twice every 3-week period . You also bone marrow sample collect every 3 month treatment . After end treatment , blood bone marrow sample collect every 3 month disease get bad start different therapy . The blood bone marrow sample use look response therapy . This investigational study . Denileukin diftitox approve FDA treatment skin T-cell lymphoma commercially available . The use denileukin diftitox study investigational . You provide denileukin diftitox free charge . Up 25 participant take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Mastocytosis , Systemic</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Patients SM , include mast cell leukemia ( MCL ) . ECOG Performance Status ( PS ) 03 Adequate renal function ( indicated serum creatinine &lt; /= 2.5 mg/dL ) ; adequate hepatic function ( indicated ALT &lt; /= 3 * upper limit normal ; total bilirubin &lt; /= 3 * upper limit normal ; albumin &gt; /= 2.8 g/dL ) . Provide write informed consent . Female patient childbearing potential must negative pregnancy test within 14 day prior first dose study drug , must agree use effective mean contraception follow pregnancy test , throughout study least three week last treatment protocol . History hypersensitivity diphtheria toxin . Active cardiovascular disease define New York Heart Association ( NYHA ) Class IIIIV categorization . Serious intercurrent medical illness active infection require parenteral antibiotic would interfere ability patient carry treatment program . Concurrent malignancy ( resect basal squamous cell skin cancer insitu cervical cancer ) . Unless , patient SMassociated clonal hematologic disease require therapy , judge treat physician approve principal investigator . Female patient pregnant breastfeeding . No chemotherapy , radiotherapy , immunotherapy , hormonal anticancer therapy , experimental medication ( include approve drug test investigational setting ) may administer patient participant protocol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Systemic Mastocytosis</keyword>
	<keyword>SM</keyword>
	<keyword>Mast Cell Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Denileukin Diftitox</keyword>
	<keyword>Ontak</keyword>
</DOC>